Literature DB >> 29382951

Hepatitis: No cure for hepatitis B and D without targeting integrated viral DNA?

Markus Cornberg1, Michael P Manns1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29382951     DOI： 10.1038/nrgastro.2017.185

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  10 in total

Review 1.  What is new on HBsAg and other diagnostic markers in HBV infection?

Authors:  Christoph Höner Zu Siederdissen; Benjamin Maasoumy; Markus Cornberg
Journal:  Best Pract Res Clin Gastroenterol       Date:  2017-05-04       Impact factor: 3.043

2.  RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg.

Authors:  Christine I Wooddell; Man-Fung Yuen; Henry Lik-Yuen Chan; Robert G Gish; Stephen A Locarnini; Deborah Chavez; Carlo Ferrari; Bruce D Given; James Hamilton; Steven B Kanner; Ching-Lung Lai; Johnson Y N Lau; Thomas Schluep; Zhao Xu; Robert E Lanford; David L Lewis
Journal:  Sci Transl Med       Date:  2017-09-27       Impact factor: 17.956

Review 3.  Molecular biology of hepatitis B virus infection.

Authors:  Christoph Seeger; William S Mason
Journal:  Virology       Date:  2015-03-07       Impact factor: 3.616

4.  Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo.

Authors:  Lena Allweiss; Tassilo Volz; Katja Giersch; Janine Kah; Giuseppina Raffa; Joerg Petersen; Ansgar W Lohse; Concetta Beninati; Teresa Pollicino; Stephan Urban; Marc Lütgehetmann; Maura Dandri
Journal:  Gut       Date:  2017-04-20       Impact factor: 23.059

5.  EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.

Authors: 
Journal:  J Hepatol       Date:  2017-04-18       Impact factor: 25.083

6.  Structural organization of the hepatitis B virus minichromosome.

Authors:  C T Bock; S Schwinn; S Locarnini; J Fyfe; M P Manns; C Trautwein; H Zentgraf
Journal:  J Mol Biol       Date:  2001-03-16       Impact factor: 5.469

Review 7.  Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection.

Authors:  Antonio Bertoletti; Carlo Ferrari
Journal:  Gut       Date:  2011-12-09       Impact factor: 23.059

Review 8.  Novel targets for hepatitis B virus therapy.

Authors:  Barbara Testoni; David Durantel; Fabien Zoulim
Journal:  Liver Int       Date:  2017-01       Impact factor: 5.828

Review 9.  The role of quantitative hepatitis B surface antigen revisited.

Authors:  Markus Cornberg; Vincent Wai-Sun Wong; Stephen Locarnini; Maurizia Brunetto; Harry L A Janssen; Henry Lik-Yuen Chan
Journal:  J Hepatol       Date:  2016-08-27       Impact factor: 25.083

10.  Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study.

Authors:  Pavel Bogomolov; Alexander Alexandrov; Natalia Voronkova; Maria Macievich; Ksenia Kokina; Maria Petrachenkova; Thorsten Lehr; Florian A Lempp; Heiner Wedemeyer; Mathias Haag; Matthias Schwab; Walter E Haefeli; Antje Blank; Stephan Urban
Journal:  J Hepatol       Date:  2016-04-27       Impact factor: 25.083
  10 in total
  7 in total

Review 1.  [Chronic hepatitis B and D (delta) : Current and future treatments].

Authors:  N Wortmann; C Höner Zu Siederdissen; M Cornberg
Journal:  Internist (Berl)       Date:  2018-06       Impact factor: 0.743

Review 2.  Transaminase Elevations during Treatment of Chronic Hepatitis B Infection: Safety Considerations and Role in Achieving Functional Cure.

Authors:  Andrew Vaillant
Journal:  Viruses       Date:  2021-04-23       Impact factor: 5.048

Review 3.  An Overview of Hepatitis B Virus Surface Antigen Secretion Inhibitors.

Authors:  Alireza Mohebbi; Nazanin Lorestani; Alireza Tahamtan; Niki L Kargar; Alijan Tabarraei
Journal:  Front Microbiol       Date:  2018-04-05       Impact factor: 5.640

4.  Permanent Inactivation of HBV Genomes by CRISPR/Cas9-Mediated Non-cleavage Base Editing.

Authors:  Yu-Chan Yang; Yu-Hsiang Chen; Jia-Horng Kao; Chi Ching; I-Jung Liu; Chih-Chiang Wang; Cheng-Hsueh Tsai; Fang-Yi Wu; Chun-Jen Liu; Pei-Jer Chen; Ding-Shinn Chen; Hung-Chih Yang
Journal:  Mol Ther Nucleic Acids       Date:  2020-03-19       Impact factor: 8.886

5.  The HBV Core Protein and Core Particle Both Bind to the PPiase Par14 and Par17 to Enhance Their Stabilities and HBV Replication.

Authors:  Umar Saeed; Zahra Zahid Piracha; Hyeonjoong Kwon; Jumi Kim; Fadia Kalsoom; Yong-Joon Chwae; Sun Park; Ho-Joon Shin; Hyun Woong Lee; Jin Hong Lim; Kyongmin Kim
Journal:  Front Microbiol       Date:  2021-12-14       Impact factor: 5.640

6.  Correlations between serum hepatitis B core-related antigen and hepatitis B surface antigen in patients with hepatitis B cirrhosis and a hepatitis B virus-DNA-negative status: a retrospective study.

Authors:  Baiguo Xu; Anjing Liu; Ying Liu; Tao Han; Hua Guo; Xian Ding; Huiling Xiang
Journal:  J Int Med Res       Date:  2022-10       Impact factor: 1.573

Review 7.  Chronic Viral Hepatitis: Current Management and Future Directions.

Authors:  Albert Do; Nancy S Reau
Journal:  Hepatol Commun       Date:  2020-01-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.